Blaze Bioscience, Inc. is focused on enhancing the surgical treatment of cancer, particularly in pediatric patients with brain tumors, through its innovative Tumor Paint® technology. This technology utilizes a fluorescent agent, specifically BLZ-100 (tozuleristide), which binds to cancer cells, allowing for real-time visualization during surgery. The CANVAS® imaging system complements this by providing enhanced imaging capabilities, making it easier for surgeons to detect and remove tumors accurately. The primary aim of this technology is to improve the sensitivity and reliability of cancer detection and treatment, especially for early-stage cancers where the potential for a cure is higher.

The company is actively engaged in clinical trials to evaluate the effectiveness and safety of its Tumor Paint products. The ongoing studies, including a randomized, blinded trial for pediatric brain cancer, are crucial for advancing the understanding and application of these technologies in clinical settings. Blaze Bioscience emphasizes the importance of collaboration with patients, caregivers, and healthcare providers in these trials, as they play a vital role in the development of new therapeutics and imaging solutions that could significantly impact cancer surgery outcomes.

United States

Blaze Bioscience, Inc. is a privately held biotechnology company dedicated to improving the lives of cancer patients, starting with kids undergoing brain cancer surgery. By leveraging our Tumor Paint technology®, including the CANVAS Imaging system® and our CDP Discovery Platform, our goal is to make the detection, removal, and treatment of all cancers sensitive, reliable, and accessible, especially early-stage cancers where cure may still be possible.

Blaze Bioscience

Company Details